---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-147984"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T19:02:55.242152+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology sells Cullinan Pearl to Taiho for $275M; co-develop CLN-081 in U.S.

## Summary
- Taiho will acquire Cullinan Pearl for $275M upfront, plus up to $130M in regulatory milestones.
- Cullinan and Taiho will co-develop and co-commercialize CLN-081 (EGFR exon20 inhibitor) in the U.S., sharing profits 50/50.
- As of March 31, 2022, cash and investments were $410M; including $275M upfront, pro forma $685M.
- Cash runway extended to 2026 from prior guidance of 2024, excluding potential milestones and U.S. profit share.
- Acquisition expected to close in Q2 2022, subject to HSR and other customary conditions.

## SEC filing metadata
- accession: 0001193125-22-147984
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312522147984/0001193125-22-147984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312522147984/d303365d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-147984
- JSON: https://secwatch.observer/filing/0001193125-22-147984.json
- Plain text: https://secwatch.observer/filing/0001193125-22-147984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.